Sign in

    Justin Steven Smith • Bernstein

    Justin Steven Smith's questions to AstraZeneca PLC (AZN) leadership

    Justin Steven Smith's questions to AstraZeneca PLC (AZN) leadership • Q4 2024

    Question

    Justin Steven Smith of Bernstein asked about the rare disease drug efzimfotase, specifically its cost of goods compared to Strensiq, and also inquired about the outlook for capital expenditures beyond 2025.

    Answer

    Marc Dunoyer, EVP of Rare Disease, confirmed that the cost of goods for efzimfotase is significantly lower than for Strensiq, which will help support the goal of reaching a much larger patient population. CFO Aradhana Sarin stated that the current elevated level of CapEx should be expected for the next several years, as it supports multiyear manufacturing and technology projects already underway.

    Ask Fintool Equity Research AI

    Justin Steven Smith's questions to GSK plc (GSK) leadership

    Justin Steven Smith's questions to GSK plc (GSK) leadership • Q4 2024

    Question

    Justin Steven Smith of AllianceBernstein asked about the resonance of the Minimal Residual Disease (MRD) endpoint in the DREAMM-10 first-line trial for Blenrep with payers and community doctors, particularly outside the U.S.

    Answer

    An executive, likely Chief Scientific Officer Tony Wood, explained that MRD is a newer endpoint recommended by ODAC, with the goal of establishing its correlation with established endpoints like PFS over time. CCO Luke Miels added that market research indicates physicians view MRD as a practical necessity for long first-line trials, but it does not replace overall survival data in later lines of therapy, where Blenrep has demonstrated strong results.

    Ask Fintool Equity Research AI